Scotiabank Maintains Sector Outperform on Ocular Therapeutix, Lowers Price Target to $20

Benzinga · 08/06/2025 16:35
Scotiabank analyst Greg Harrison maintains Ocular Therapeutix (NASDAQ:OCUL) with a Sector Outperform and lowers the price target from $22 to $20.